These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 28628038)

  • 1. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.
    Yang S; Chang R; Yang H; Zhao T; Hong Y; Kong HE; Sun X; Qin Z; Jin P; Li S; Li XJ
    J Clin Invest; 2017 Jun; 127(7):2719-2724. PubMed ID: 28628038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
    Shin JW; Kim KH; Chao MJ; Atwal RS; Gillis T; MacDonald ME; Gusella JF; Lee JM
    Hum Mol Genet; 2016 Oct; 25(20):4566-4576. PubMed ID: 28172889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo.
    Monteys AM; Ebanks SA; Keiser MS; Davidson BL
    Mol Ther; 2017 Jan; 25(1):12-23. PubMed ID: 28129107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities.
    Oikemus SR; Pfister EL; Sapp E; Chase KO; Kennington LA; Hudgens E; Miller R; Zhu LJ; Chaudhary A; Mick EO; Sena-Esteves M; Wolfe SA; DiFiglia M; Aronin N; Brodsky MH
    Hum Gene Ther; 2022 Jan; 33(1-2):25-36. PubMed ID: 34376056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of Dual-Single Guide RNA CRISPR Strategies for the Treatment of Central Nervous System Genetic Disorders.
    Duarte F; Vachey G; Caron NS; Sipion M; Rey M; Perrier AL; Hayden MR; Déglon N
    Hum Gene Ther; 2023 Sep; 34(17-18):958-974. PubMed ID: 37658843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of Endogenous Mutant Huntingtin in Astrocytes Exacerbates Neuropathology of Huntington Disease in Mice.
    Jing L; Cheng S; Pan Y; Liu Q; Yang W; Li S; Li XJ
    Mol Neurobiol; 2021 Oct; 58(10):5112-5126. PubMed ID: 34250577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR takes on Huntington's disease.
    Eisenstein M
    Nature; 2018 May; 557(7707):S42-S43. PubMed ID: 29844549
    [No Abstract]   [Full Text] [Related]  

  • 9. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
    Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
    Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington's Disease.
    Alkanli SS; Alkanli N; Ay A; Albeniz I
    Mol Neurobiol; 2023 Mar; 60(3):1486-1498. PubMed ID: 36482283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meso scale discovery-based assays for the detection of aggregated huntingtin.
    Reindl W; Baldo B; Schulz J; Janack I; Lindner I; Kleinschmidt M; Sedaghat Y; Thiede C; Tillack K; Schmidt C; Cardaun I; Schwagarus T; Herrmann F; Hotze M; Osborne GF; Herrmann S; Weiss A; Zerbinatti C; Bates GP; Bard J; Munoz-Sanjuan I; Macdonald D
    PLoS One; 2019; 14(3):e0213521. PubMed ID: 30913220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-Mediated Genome Editing for Huntington's Disease.
    Vachey G; Déglon N
    Methods Mol Biol; 2018; 1780():463-481. PubMed ID: 29856031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant Huntingtin Inhibits αB-Crystallin Expression and Impairs Exosome Secretion from Astrocytes.
    Hong Y; Zhao T; Li XJ; Li S
    J Neurosci; 2017 Sep; 37(39):9550-9563. PubMed ID: 28893927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA double-strand break-free CRISPR interference delays Huntington's disease progression in mice.
    Seo JH; Shin JH; Lee J; Kim D; Hwang HY; Nam BG; Lee J; Kim HH; Cho SR
    Commun Biol; 2023 Apr; 6(1):466. PubMed ID: 37117485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is a key pathogenic form.
    Yang H; Yang S; Jing L; Huang L; Chen L; Zhao X; Yang W; Pan Y; Yin P; Qin ZS; Tang B; Li S; Li XJ
    Nat Commun; 2020 May; 11(1):2582. PubMed ID: 32444599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HuR stabilizes
    Zhao Q; Li C; Yu M; Sun Y; Wang J; Ma L; Sun X; Lu B
    RNA Biol; 2020 Apr; 17(4):500-516. PubMed ID: 31928144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allele-specific silencing of the gain-of-function mutation in Huntington's disease using CRISPR/Cas9.
    Shin JW; Hong EP; Park SS; Choi DE; Seong IS; Whittaker MN; Kleinstiver BP; Chen RZ; Lee JM
    JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice.
    Petkau TL; Hill A; Connolly C; Lu G; Wagner P; Kosior N; Blanco J; Leavitt BR
    Hum Mol Genet; 2019 May; 28(10):1661-1670. PubMed ID: 30624705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology.
    Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.